Secondary bladder cancer after permanent iodine-125 brachytherapy for prostate cancer
-
- Hirayama Kidai
- Department of Urology, Showa University Graduate School of Medicine Department of Urology, Showa University School of Medicine
-
- Fukagai Takashi
- Department of Urology, Showa University School of Medicine
-
- Morita Masashi
- Department of Urology, Showa University School of Medicine
-
- Oshinomi Kazuhiko
- Department of Urology, Showa University School of Medicine
-
- Nishimura Kota
- Department of Urology, Showa University School of Medicine
-
- Yamatoya Jin
- Department of Urology, Showa University School of Medicine
-
- Nakagami Yoshihiro
- Department of Urology, Showa University School of Medicine
-
- Toyofuku Kosuke
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
-
- Niiya Akifumi
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
-
- Kobayashi Rei
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
-
- Nishimura Emi
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
-
- Kato Masako
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
-
- Morota Madoka
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
-
- Ito Yoshinori
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine
抄録
Bladder cancer has been observed in patients after permanent iodine-125 brachytherapy (hereafter referred to as brachytherapy) for prostate cancer. We investigated secondary bladder cancer after brachytherapy. From January 2005 to March 2021, a total of 1,478 patients underwent brachytherapy for localized prostate cancer at Showa University Hospital and Showa University Koto Toyosu Hospital. A standardized incidence rate was calculated from the incidence of secondary bladder cancer after brachytherapy and compared with the national cancer registry general incidence data. The median follow-up was 4.7 years. Secondary bladder cancer occurred in 15 of 1478 patients (median age: 71 years). The incidence was 198 cases/100,000 persons/year. The incidence was 2.84 times higher than that of Japan’s national cancer registry. In addition, as a characteristic of secondary bladder cancer, the malignancy tended to be high regardless of the depth of invasion. The relative risk between cases with a secondary bladder cancer period until occurrence of >5 years and cases with a secondary bladder cancer period until occurrence of ≤5 years was 1.61 times (95% CI: 0.57-4.50), but the difference was not significant. In this study, we found that the incidence of bladder cancer was 2.84 times higher than that of the general population of Japan, suggesting that brachytherapy increases the risk of developing bladder cancer. To our knowledge, this study is the first to compare the incidence of brachytherapy and general bladder cancer in Japan. The results of this study suggest that although brachytherapy is effective for prostate cancer, attention should be paid to the early detection of bladder cancer because of the risk of secondary cancer development.
収録刊行物
-
- The Showa University Journal of Medical Sciences
-
The Showa University Journal of Medical Sciences 35 (2), 39-45, 2023
昭和大学学士会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390578381962582784
-
- ISSN
- 21850968
- 09156380
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
-
- 抄録ライセンスフラグ
- 使用不可